Orexo´s Nomination Committee for the Annual General Meeting 2023
Orexo has appointed a Nomination Committee ahead of its Annual General Meeting (AGM) scheduled for April 18, 2023. The committee includes Christian Salling, Claus Berner Møller, Patrik Walldov, and James Noble, representing approximately 38% of voting rights as of September 30, 2022. The committee will propose key governance decisions, including the Chairman of the Meeting and Board members' remuneration. Shareholders can submit proposals to the Nomination Committee until February 17, 2023. Orexo specializes in pharmaceuticals for substance use disorders, with notable sales of SEK 565 million in 2021.
- Nomination Committee appointed for AGM 2023, ensuring shareholder representation.
- Committee represents approximately 38% of voting rights, enhancing governance.
- None.
UPPSALA, Sweden, Oct. 17, 2022 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same members as ahead of the AGM hosted earlier this year:
- Christian Salling, Novo Holdings A/S, also Chairman of the Nomination Committee
- Claus Berner Møller, ATP
- Patrik Walldov, representative for Anders Walldov (incl. indirect holding via Brohuvudet AB)
- James Noble, Chairman of the Board of Orexo
The shareholders having appointed members of the Nomination Committee together represent approximately 38 percent of the voting rights as of September 30, 2022.
The Nomination Committee will prepare proposals to the AGM regarding Chairman of the Meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor, as well as principles for the composition of the Nomination Committee.
The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com.
Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject "Nomination Committee") or by letter posted to "Orexo's Nomination Committee", Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by February 17, 2023 at the latest.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director |
Tel: +46 (0)18 780 88 00 |
E-mail: ir@orexo.com |
About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.
The information was submitted for publication at 3 pm CET, on October 17, 2022.
View original content:https://www.prnewswire.com/news-releases/orexos-nomination-committee-for-the-annual-general-meeting-2023-301650828.html
SOURCE Orexo
FAQ
What is the date of Orexo's Annual General Meeting (AGM) in 2023?
Who are the members of Orexo's Nomination Committee?
What percentage of voting rights does the Nomination Committee represent?
How can shareholders submit proposals to Orexo's Nomination Committee?
What were Orexo's total net sales for 2021?
